Search results
Showing 166 to 180 of 565 results for oral care
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
CG151/5 Question Switching from inpatient intravenous to outpatient oral antibiotic therapy in patients with neutropenic sepsis:- A...
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
View recommendations for TA217Show all sections
This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol-use disorder and caring for people with alcohol-related health problems, as well as support for their families and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS11Show all sections
Sections for QS11
- Quality statements
- Quality statement 1: Use of validated alcohol questionnaires
- Quality statement 2: Community support networks and self-help groups
- Quality statement 3: Triage assessment in specialist alcohol services
- Quality statement 4: Acute alcohol withdrawal
- Quality statement 5: Interventions to prevent relapse after unplanned withdrawal from alcohol in hospital
- Update information
- About this quality standard
This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS25Show all sections
Sections for QS25
- Quality statements
- Quality statement 1: Objective tests to support diagnosis
- Quality statement 2: Documented personalised action plan
- Quality statement 3: Monitoring asthma control
- Quality statement 4: Follow-up by general practice after emergency care
- Quality statement 5 (developmental): Suspected severe asthma
- Update information
- About this quality standard
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.